Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Double mapping with subareolar blue dye and peritumoral green dye injections decreases the false-negative rate of dye-only sentinel node biopsy for early breast cancer: 2-site injection is more accurate than 1-site injection.
Anan K, Mitsuyama S, Kuga H, Saimura M, Tanabe Y, Suehara N, Matsunaga H, Nishihara K, Abe Y, Iwashita T, Ihara T, Tamae K, Ono M, Toyoshima S. Anan K, et al. Among authors: saimura m. Surgery. 2006 May;139(5):624-9. doi: 10.1016/j.surg.2005.11.007. Surgery. 2006. PMID: 16701094
Disparities in the survival improvement of recurrent breast cancer.
Anan K, Mitsuyama S, Koga K, Tanabe R, Saimura M, Tanabe Y, Watanabe M, Suehara N, Matsunaga H, Nishihara K, Abe Y, Nakano T, Tamae K, Ono M, Toyoshima S. Anan K, et al. Among authors: saimura m. Breast Cancer. 2010;17(1):48-55. doi: 10.1007/s12282-009-0103-2. Epub 2009 Apr 7. Breast Cancer. 2010. PMID: 19350357
Efficacy and safety of eribulin as first- to third-line treatment in patients with advanced or metastatic breast cancer previously treated with anthracyclines and taxanes.
Maeda S, Saimura M, Minami S, Kurashita K, Nishimura R, Kai Y, Yano H, Mashino K, Mitsuyama S, Shimokawa M, Tamura K; Kyushu Breast Cancer Study Group. Maeda S, et al. Among authors: saimura m. Breast. 2017 Apr;32:66-72. doi: 10.1016/j.breast.2016.12.017. Epub 2017 Jan 3. Breast. 2017. PMID: 28056400 Clinical Trial.
Role of HER2-Related Biomarkers (HER2, p95HER2, HER3, PTEN, and PIK3CA) in the Efficacy of Lapatinib plus Capecitabine in HER2-Positive Advanced Breast Cancer Refractory to Trastuzumab.
Nishimura R, Toh U, Tanaka M, Saimura M, Okumura Y, Saito T, Tanaka T, Teraoka M, Shimada K, Katayama K, Koga T, Kurashita K, Hasegawa S, Todoroki H, Kai Y, Ohi Y, Toyoshima S, Arima N, Mitsuyama S, Tamura K. Nishimura R, et al. Among authors: saimura m. Oncology. 2017;93(1):51-61. doi: 10.1159/000468521. Epub 2017 May 6. Oncology. 2017. PMID: 28478451
49 results